Altasciences announced that construction work has begun on the expansion of their ligand binding laboratory to meet the high demand for quality bioanalytical services. The additional space will include a fully-equipped, state-of-the-art lab dedicated to ligand binding and cell based assays.
The lab expansion will enable Altasciences to sustain increased requests for cell based neutralization and functional assays in both clinical safety and efficacy assessment for biologics and vaccines respectively. In addition, Altasciences will be able to accommodate higher demand for multi-color phenotyping by flow cytometry to support PK, immuno-toxicology, and biomarkers for preclinical and clinical studies.
“This expansion is a result of the industry identifying Altasciences as a key partner in bioanalysis. Our scientific knowledge, flexible and customized approach, as well as our continual focus on quality are cornerstones of our success. The current expansion demonstrates our commitment to meet the evolving and increasingly complex needs of sponsors,” stated Danielle Salha, Altasciences’ director, Ligand Binding Assays.
Altasciences’ bioanalytical team consists of more than 100 dedicated bioanalytical specialists who work with the latest equipment to provide a comprehensive suite of bioanalytical services, from discovery to preclinical to phase IV clinical support, for both small and large molecules.